Literature DB >> 29162719

Limiting Factors in Walking Performance of Subjects With COPD.

Marcela Alves Sanseverino1, Matteo Pecchiari2, Renata Luisa Bona3, Danilo Cortozi Berton1,4,5, Francisco Busolli de Queiroz1,4,5,6, Mathieu Gruet7, Leonardo A Peyré-Tartaruga8,6.   

Abstract

INTRODUCTION: Exercise intolerance is the most predominant symptom in patients with COPD. Nevertheless, it is unclear whether walking economy and gait variability are altered in these patients. Thus, our main objective was to compare the cost of transport and gait variability as a function of speed, including the self-selected walking speed, in subjects with COPD relative to healthy subjects.
METHODS: 22 subjects, 11 with COPD (FEV1 = 45 ± 17% of predicted) and 11 age- and sex-matched healthy subjects undertook an evaluation that involved walking on a treadmill at 6 speeds (at 3.2 km/h, at a self-selected walking speed, and at 2 speeds below and 2 speeds above the self-selected walking speed) and measuring the cost of transport (the oxygen consumption normalized by mass and distance), gait variability, perceived dyspnea, and leg fatigue.
RESULTS: In subjects with COPD, the cost of transport decreased with increasing walking speed, contrary to healthy subjects, who presented a minimum at the self-selected walking speed. No difference was found in cost of transport between the experimental groups at the same absolute velocity (P = .62). In subjects with COPD, dyspnea sensation rose above the self-selected walking speed, doubling at the maximal walking velocity (P = .03), and gait variability was higher at low speeds.
CONCLUSION: Subjects with COPD choose their walking speed so as to keep the dyspnea sensation tolerable and to keep gait variability and cost of transport at an acceptable level. These outcomes suggest that interventions acting on dyspnea and gait pattern may increase patients' self-selected walking speed and improve their quality of life.
Copyright © 2018 by Daedalus Enterprises.

Entities:  

Keywords:  chronic obstructive pulmonary disease; dyspnea; fatigue; gait; oxygen consumption; walking speed

Mesh:

Year:  2017        PMID: 29162719     DOI: 10.4187/respcare.05768

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Energy efficient physiologic coupling of gait and respiration is altered in chronic obstructive pulmonary disease.

Authors:  Jennifer M Yentes; William Denton; Kaeli Samson; Kendra K Schmid; Casey Wiens; Stephen I Rennard
Journal:  Acta Physiol (Oxf)       Date:  2018-12-07       Impact factor: 6.311

2.  Effects of Nordic walking training on quality of life, balance and functional mobility in elderly: A randomized clinical trial.

Authors:  Natalia Andrea Gomeñuka; Henrique Bianchi Oliveira; Edson Soares Silva; Rochelle Rocha Costa; Ana Carolina Kanitz; Giane Veiga Liedtke; Felipe Barreto Schuch; Leonardo A Peyré-Tartaruga
Journal:  PLoS One       Date:  2019-01-30       Impact factor: 3.240

3.  Enhancing instantaneous oxygen uptake estimation by non-linear model using cardio-pulmonary physiological and motion signals.

Authors:  Zhao Wang; Qiang Zhang; Ke Lan; Zhicheng Yang; Xiaolin Gao; Anshuo Wu; Yi Xin; Zhengbo Zhang
Journal:  Front Physiol       Date:  2022-08-25       Impact factor: 4.755

4.  Factors influencing self-selected walking speed in fibrotic interstitial lung disease.

Authors:  Gabriela Fischer; Francisco B de Queiroz; Danilo C Berton; Pedro Schons; Henrique B Oliveira; Marcelo Coertjens; Mathieu Gruet; Leonardo A Peyré-Tartaruga
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

Review 5.  Fatigue in Chronic Respiratory Diseases: Theoretical Framework and Implications For Real-Life Performance and Rehabilitation.

Authors:  Mathieu Gruet
Journal:  Front Physiol       Date:  2018-09-19       Impact factor: 4.566

6.  Metabolic cost in healthy fit older adults and young adults during overground and treadmill walking.

Authors:  Sauvik Das Gupta; Maarten Bobbert; Herre Faber; Dinant Kistemaker
Journal:  Eur J Appl Physiol       Date:  2021-06-21       Impact factor: 3.078

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.